- Basic Science
- Podcast Series
- Targeted Therapies in Lung Cancer 2023
- ASCO® 2023
- Lung Cancer OncTalk
- Blood Cancer OncTalk
- 2022 Melanoma Video Library
- OncTalk 2022
- ASCO Lung Review 2022
- ASCO and ESMO Lung Recap
- 2021 Targeted Therapies Patient Forum
- COVID-19
- Lung
- Hematologic Oncology
- Head and Neck
- Brain
- Palliative
- Genitourinary
- General
- Breast
Playback speed
10 seconds
Targeted Therapy for EGFR+ NSCLC: What Are the Current Options Upon Acquired Resistance to Osimertinib?
By
GRACE
FEATURING
Zofia Piotrowska
By
GRACE
FEATURING
Zofia Piotrowska
104 views
March 1, 2021
Comments 0
Login to view comments.
Click here to Login